Growth hormone producing gene therapy - DNARx
Alternative Names: HEDGESTM gene therapies - DNARx; hGH producing gene therapy – DNARxLatest Information Update: 27 May 2021
At a glance
- Originator DNARx
- Class Gene therapies
- Mechanism of Action Gene transference; Human growth hormone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Somatotropin deficiency
Most Recent Events
- 11 May 2021 Research programme: gene therapies - DNARx is available for licensing as of 11 May 2021. https://dnarx.net/contact/
- 20 Mar 2021 Preclinical trials in Somatotropin deficiency in USA (Parenteral)
- 20 Mar 2021 Pharmacodynamics data from a preclinical trial in Growth disorders presented at 103rd Annual Meeting of the Endocrine Society (ENDO-2021)